Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has achieved a significant breakthrough in its globalization efforts, with high-end models signed in over 40 countries and nearly 300 units sold [7] - The domestic market share has further increased despite an overall slowdown in the industry, with a strong product mix enhancing competitive advantages [7] - The company's revenue for 2024 is projected to be 10.3 billion yuan, a decrease of 9.73% year-on-year, with a net profit of 1.262 billion yuan, down 36.08% year-on-year [7] - The first quarter of 2025 shows signs of recovery, with revenue of 2.478 billion yuan, an increase of 5.42% year-on-year, and a net profit of 370 million yuan, up 1.87% year-on-year [7] - The company maintains a strong competitive position due to high product barriers and is expected to benefit from a recovery in the domestic industry [7] Financial Summary - Total revenue for 2023 is 11.411 billion yuan, with a projected decline to 10.3 billion yuan in 2024, followed by a recovery to 11.599 billion yuan in 2025 [1][8] - The net profit for 2023 is 1.974 billion yuan, expected to drop to 1.262 billion yuan in 2024, and then rise to 1.587 billion yuan in 2025 [1][8] - The earnings per share (EPS) is projected to decrease from 2.40 yuan in 2023 to 1.53 yuan in 2024, before recovering to 1.93 yuan in 2025 [1][8] - The price-to-earnings (P/E) ratio is expected to be 86.80 in 2024, decreasing to 69.03 in 2025 and further to 51.20 in 2026 [1][8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has achieved a significant breakthrough in its globalization efforts, with high-end models signed in nearly 300 units across over 40 countries [7] - The domestic market share has further increased despite an overall slowdown in the industry, with a strong product mix enhancing competitive advantages [7] - The company's revenue for 2024 is projected to be 10.3 billion yuan, a decrease of 9.73% year-on-year, while the net profit attributable to shareholders is expected to be 1.262 billion yuan, down 36.08% year-on-year [7] - The first quarter of 2025 shows signs of recovery, with a revenue of 2.478 billion yuan, an increase of 5.42% year-on-year, and a net profit of 370 million yuan, up 1.87% year-on-year [7] - The company maintains a strong competitive position with high product barriers and is expected to benefit from a recovery in the domestic industry [7] Financial Summary - Total revenue for 2023 is 11.411 billion yuan, with a projected decline to 10.3 billion yuan in 2024, followed by a recovery to 11.599 billion yuan in 2025 [1][8] - The net profit attributable to shareholders is forecasted to decrease from 1.974 billion yuan in 2023 to 1.262 billion yuan in 2024, before increasing to 1.587 billion yuan in 2025 [1][8] - The earnings per share (EPS) is expected to decline from 2.40 yuan in 2023 to 1.53 yuan in 2024, with a recovery to 1.93 yuan in 2025 [1][8] - The price-to-earnings (P/E) ratio is projected to be 86.80 for 2024, decreasing to 69.03 in 2025 and further to 51.20 in 2026 [1][8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company has shown impressive growth in overseas business and has made significant breakthroughs in high-end products [5] - Revenue forecasts for 2025-2027 are projected at 126.04 billion, 151.57 billion, and 182.24 billion yuan, with year-on-year growth rates of 22.37%, 20.25%, and 20.24% respectively [6] - The net profit attributable to the parent company for the same period is expected to be 18.71 billion, 22.87 billion, and 27.87 billion yuan, with growth rates of 48.26%, 22.23%, and 21.85% respectively [6] Financial Performance Summary - In 2024, the company achieved a revenue of 103.00 billion yuan (down 9.73% year-on-year) and a net profit of 12.62 billion yuan (down 36.09% year-on-year) [8] - For Q1 2025, the company reported a revenue of 24.78 billion yuan (up 5.42% year-on-year) and a net profit of 3.70 billion yuan (up 1.87% year-on-year) [8] - The company's main business gross margin for 2024 was 49.40%, an increase of 1.85 percentage points year-on-year [8] Market Position and Product Development - The company has seen a steady increase in domestic market share, with a rise of over 3 percentage points, and a nearly 5 percentage point increase in high-end product market share [8] - The company launched over 140 innovative products by the end of 2024, with 49 products receiving FDA registration [8]

医药生物/医疗器械 联影医疗（688271.SH） 国内市场蓄势待发，海外市场高歌猛进 2025 年 04 月 30 日 《打破医学影像垄断格局，国内市占 持续提升+海外装机快速放量驱动业 绩强势增长—公司首次覆盖报告》 -2025.3.12 余汝意（分析师） 石启正（联系人） 日期 2025/4/30 当前股价(元) 132.90 一年最高最低(元) 152.00/92.00 总市值(亿元) 1,095.31 流通市值(亿元) 788.49 总股本(亿股) 8.24 流通股本(亿股) 5.93 近 3 个月换手率(%) 46.1 司 信 息 更 新 报 告 股价走势图 -48% -32% -16% 0% 16% 32% 2024-04 2024-08 2024-12 2025-04 联影医疗 沪深300 数据来源：聚源 相关研究报告 投资评级：买入（维持） shiqizheng@kysec.cn 证书编号：S0790125020004 国内招采回暖，业绩有望快速放量，海外市场高歌猛进，维持"买入"评级 2024年实现营业收入103.00亿元（yoy-9.73%），归母净利润12.62亿元（yoy-36.09 ...

Group 1 - The core viewpoint of the news is the performance and holdings of the Industrial and Commercial Bank of China Medical Healthcare Stock Fund, which has shown positive growth in recent months and has a diversified portfolio in the healthcare sector [1][3]. - As of April 30, 2025, the latest net value of the fund is 2.5180 yuan, reflecting a growth of 1.82%. The fund's return over the past month is 2.07%, ranking 41 out of 469 in its category. Over the past three months, the return is 11.71%, ranking 45 out of 467, and since the beginning of the year, the return is 10.49%, ranking 44 out of 465 [1]. - The fund's total assets amount to 2.724 billion yuan as of March 31, 2025, and it was established on November 18, 2014. The fund managers are Zhao Bei and Ding Yang [1]. Group 2 - The top ten holdings of the fund account for a total of 39.79%, with significant investments in companies such as Heng Rui Pharmaceutical (8.90%), WuXi AppTec (5.12%), and Aier Eye Hospital (4.94%) [1]. - Zhao Bei, the fund manager, has extensive experience in the healthcare sector, having been with ICBC Credit Suisse Asset Management since 2010 and managing the healthcare fund since its inception in 2014. Ding Yang, the co-manager, has a strong academic background and joined the firm in 2017 [2].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][44]. Core Insights - The pharmaceutical sector has shown strong performance compared to the overall market, with a 1.16% increase in the biopharmaceutical sector [1][33]. - Multiple domestic innovative drug molecules are set to present important clinical data at the ASCO annual meeting, highlighting the growing global competitiveness of Chinese pharmaceutical companies [2][12]. - The report suggests focusing on companies with high-quality innovation capabilities, such as Innovent Biologics, Kelun Biotech, and others [2][12]. Summary by Sections Market Performance - The overall A-share market increased by 0.95%, with the biopharmaceutical sector outperforming the market [1][33]. - The TTM P/E ratio for the biopharmaceutical sector is 30.67x, which is at the 61.96% percentile of the past five years [1][40]. Fund Holdings Analysis - In Q1 2025, the total fund holdings in the pharmaceutical sector increased to 9.05%, up by 0.47 percentage points [3][20]. - The largest sub-sectors in terms of holdings are chemical preparations and CXO, with significant increases in their holdings compared to Q4 2024 [3][22]. Key Company Forecasts and Ratings - Major companies such as Mindray Medical, WuXi AppTec, and Innovent Biologics are rated as "Outperform" with projected net profits increasing over the next few years [4][46]. - For instance, Mindray Medical is expected to achieve a net profit of 115.8 billion in 2023, growing to 176.4 billion by 2026 [4]. Investment Strategy - The report emphasizes the acceleration of outbound licensing transactions for innovative drugs, suggesting that companies like Kelun Biotech and Innovent Biologics are well-positioned for growth [44][46]. - It also highlights the potential of the medical services sector, particularly in light of new policies supporting reproductive health and elderly care [45][46].

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index (000683) has seen a strong increase of 1.80%, with notable gains from stocks such as Xiangyu Medical (688626) up 7.27% and Microelectrophysiology (688351) also up 7.27% [1] - The Sci-Tech Biopharmaceutical ETF (588250) rose by 1.78%, marking its third consecutive increase, with the latest price at 1.03 yuan. Over the past month, this ETF has ranked first in its category for growth [1] - The upcoming annual American Society of Clinical Oncology (ASCO) conference is expected to enhance the outlook for innovative drugs, as Chinese experts are set to present at the event, potentially boosting the industry's sentiment [1] Group 2 - Institutions believe that the head-to-head comparison of Kangfang Biopharma's Ivosidenib shows strong positive results, reflecting the company's strength and potentially accelerating competition among similar innovative drugs [2] - The Sci-Tech Biopharmaceutical ETF closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index, which includes 50 large-cap companies in biopharmaceuticals and related fields, representing the overall performance of the sector [2] - As of March 31, 2025, the top ten weighted stocks in the Sci-Tech Biopharmaceutical Index account for 51.35% of the index, with companies like United Imaging Healthcare (688271) and BeiGene (688235) among the leaders [2]

Core Viewpoint - The Hong Kong pharmaceutical sector is experiencing a strong upward trend, with significant increases in key stocks and ETFs, driven by favorable policies and innovations in the industry [1][2][4]. Group 1: Market Performance - As of April 30, 2025, the CSI Hong Kong Stock Connect Pharmaceutical and Healthcare Composite Index (930965) rose by 1.05%, with notable increases in stocks such as MicroPort Scientific Corporation-B (02252) up 11.12% and BeiGene (06160) up 5.97% [1]. - The Hong Kong Pharmaceutical ETF (159718) increased by 0.56%, with a recent price of 0.72 HKD, and has seen a 1.56% rise over the past week, ranking among the top in its category [1][2]. - The CSI Pharmaceutical and Medical Device Innovation Index (931484) rose by 0.81%, with stocks like Kelun Pharmaceutical (002422) up 5.83% and East China Pharmaceutical (000963) up 2.70% [4]. Group 2: Trading Activity - The Hong Kong Pharmaceutical ETF recorded a turnover rate of 28.85% during trading, with a total transaction volume of 74.15 million HKD, indicating active market participation [2]. - The ETF's average daily trading volume over the past week was 112 million HKD, and it has seen a significant growth in scale, increasing by 57.33 million HKD this month, leading its category [2]. Group 3: Regulatory and Policy Developments - The Hainan Provincial Government is promoting the rapid clinical use of innovative drugs and medical devices through policy guidance and inter-departmental collaboration, aiming for high-quality development in the biopharmaceutical industry [2]. - The National Medical Products Administration (NMPA) is conducting research to enhance regulatory efficiency and support innovation in drug development, emphasizing the need for comprehensive reforms in drug regulation [2]. Group 4: Investment Opportunities - The current market conditions, including the integration of "Artificial Intelligence +" in medical applications and the emergence of new healthcare business models, present potential investment opportunities in the pharmaceutical sector [2]. - The valuation of the Hong Kong Pharmaceutical ETF, with a price-to-earnings ratio (PE-TTM) of 23.91, is at a historical low, suggesting a favorable entry point for investors [4].

Market Overview - Global markets showed mixed performance with the Hang Seng Index closing at 22,008, up 0.16% year-to-date increase of 29.10% [1] - The US markets continued to rebound, with the Dow Jones up 0.75% and the S&P 500 up 0.58%, reflecting a year-to-date increase of 7.53% and 16.58% respectively [1][3] Industry Insights - The equipment manufacturing sector reported Q1 2025 earnings, with SANY Heavy Industry exceeding expectations with a 56% year-on-year profit increase, driven by an 18% revenue growth [4] - The pharmaceutical company WuXi AppTec reported a strong Q1 2025, with revenue up 21% to 9.65 billion yuan and a non-IFRS net profit increase of 40% to 2.68 billion yuan [4][6] - Mindray Medical's revenue for 2024 was 36.7 billion yuan, a 5.1% increase, but faced challenges in the domestic market with a 12.1% decline in Q1 2025 revenue [7][8] Company Analysis - WuXi AppTec maintained its full-year guidance despite macro uncertainties, expecting a 10-15% revenue growth in its continuing operations for 2025 [4][6] - Mindray Medical's overseas revenue grew by 21.3% in 2024, accounting for 44.7% of total revenue, indicating strong international market performance [7] - Luckin Coffee reported a 41% year-on-year sales increase in Q1 2025, driven by strong same-store sales growth and rapid store expansion [11][12] Investment Ratings - SANY Heavy Industry is rated as a "Buy" with a focus on its excavator business cycle and overseas growth potential [4] - WuXi AppTec is also rated as a "Buy," with a target price of 77.22 yuan, reflecting confidence in its growth despite external challenges [6] - Mindray Medical is rated as a "Buy," with a target price of 249.19 yuan, anticipating recovery in domestic sales in the latter half of 2025 [8]

Key Insights on Fixed Income Market - The bond market experienced a significant decline followed by a period of consolidation, with the 10-year government bond yield decreasing by 15 basis points to 1.66% in April [2][3] - The supply of government bonds is expected to peak in May, with net supply projected to reach around 1.9 trillion yuan, comparable to levels seen in August of the previous year [3][4] - The central bank is likely to maintain a supportive stance on liquidity, with potential reverse repos and MLF net injections to counterbalance the impact of increased bond issuance [4][7] Key Insights on Artificial Intelligence Industry - The Central Political Bureau emphasized the importance of self-reliance and application-driven development in AI, marking a shift towards a focus on ecological construction and rule-setting in AI development [9][10] - The AI industry is expected to enter a golden window for commercialization from 2025 to 2030, with significant opportunities in various applications such as AIoT and embodied intelligence [10][11] - Key areas of focus include enhancing basic research, fostering collaboration between academia and industry, and strengthening the regulatory framework to prevent blind development in the AI sector [11] Key Insights on Pharmaceutical Industry - The pharmaceutical sector is witnessing a recovery in holdings, with public fund allocations increasing as the market stabilizes, particularly in innovative drugs and medical devices [16][19] - The introduction of a new insurance payment model is expected to stimulate the development of innovative drugs, with the first version of the Class B drug list focusing on high-innovation products [17][19] - The medical device procurement market is experiencing significant growth, with a year-on-year increase of 67.49% in Q1 2025, driven by domestic demand and the rise of local brands [18][19] Key Insights on Semiconductor Industry - The company reported a record high in revenue and net profit for 2024, with a 27.69% year-on-year increase in revenue to 7.356 billion yuan and a staggering 584.21% increase in net profit [22][23] - The growth is attributed to the strong performance of storage chips, with a gross margin of 40.27% and a focus on expanding into high-growth markets such as AI terminals and automotive electronics [23][24] - The company is strategically positioned to benefit from the acceleration of AI applications, with plans to enhance its product offerings in the storage chip sector [25] Key Insights on Food Industry - The company demonstrated resilience with a 10.3% year-on-year increase in revenue to 600 million yuan in Q1 2025, despite a challenging market environment [28][29] - The strong performance of major product lines, particularly fish and bean products, contributed to revenue growth, supported by improved channel partnerships [28][30] - The company is focusing on brand development and product innovation to enhance its market position and drive long-term growth [30]